Genocea Biosciences Inc RSI
Cos'è RSI di Genocea Biosciences Inc?
RSI di Genocea Biosciences Inc è 21.09
Qual è la definizione di RSI?
L'indice di forza relativa (RSI 14) è un indicatore di momentum che confronta l'entità dei guadagni e delle perdite in un determinato periodo di tempo per misurare la velocità e il cambiamento dei movimenti di prezzo di un titolo.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI di aziende nel Health Care settore su NASDAQ rispetto a Genocea Biosciences Inc
Cosa fa Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Aziende con rsi simili a Genocea Biosciences Inc
- Akazoo S.A ha RSI di 21.04
- Delfingen Industry SA ha RSI di 21.04
- Holiday Island ha RSI di 21.05
- Oriental Press ha RSI di 21.07
- Elanor Retail Property Fund ha RSI di 21.07
- Qantm Intellectual Property ha RSI di 21.08
- Genocea Biosciences Inc ha RSI di 21.09
- Longfor Properties Co ha RSI di 21.12
- Ssif ETF I - Ssif Dce Iron Ore Futures Index ETF ha RSI di 21.12
- Rare Earth Magnesium Technology ha RSI di 21.13
- Arcimoto ha RSI di 21.16
- VBI Vaccines ha RSI di 21.17
- Future Supply Chain Solutions ha RSI di 21.18